Eva Marchese

Vice President

Eva Marchese specializes in competitive strategy, pricing, market access, and research primarily in the pharmaceutical, biotech, and life sciences industries. She has an extensive consulting background with a focus on advising pharmaceutical, medical device companies, and medical technology (MedTech) companies on global pricing and market access. Dr. Marchese has expertise in multiple therapy areas, including oncology, immunology, biosimilars, vaccines, and tendering.

Prior to joining CRA, Dr. Marchese was Senior Principal, Pricing & Market Access at QuintilesIMS, now doing business as IQVIA, with a focus on pricing, market access, regulatory, funding, and tendering. As a Partner at Sanità & Management Consulting, Eva was involved in several ministerial committees at the Italian Ministry of Health, examining cost evaluations and analyzing healthcare organizations’ procedures. She was previously Professor of Public Management and Policy at Bocconi-SDA and a contracted Research Fellow at the Center for Research on Healthcare and Social Management at Bocconi University.

Dr. Marchese frequently presents at industry conferences and has written articles for various publications. She speaks Italian and English and is advanced in Spanish.

Selected Engagements

  • 01
    Commercial opportunity and PMA potential for radiotherapy device supporting novel procedure in cardiology
    Our client was preparing to launch an upgrade to their radiotherapy devices and wanted to understand the commercial potential, preferred business models and...
    View engagement
  • 02
    Understanding the regulatory, P&R and access landscape for medical devices
    Our client approached us to map pathways for medical devices used as part of inpatient and ambulatory procedures. Outputs were used to support an internal...
    View engagement
  • 03
    CRA evaluates commercial efforts to develop a MS drug with respect contractual obligations following merger
    CRA assessed commercial efforts to develop and commercialize a MS drug with respect to obligations stemming from the acquisition of Genzyme Corporation by...
    View engagement

Credentials